Idexx Laboratories Inc. (NASDAQ:IDXX)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $111.95 and last traded at $111.90, with a volume of 152,964 shares. The stock had previously closed at $110.78.

A number of brokerages recently issued reports on IDXX. Zacks Investment Research raised shares of Idexx Laboratories from a “hold” rating to a “buy” rating and set a $106.00 target price on the stock in a research report on Monday, July 25th. Stifel Nicolaus reaffirmed a “buy” rating and set a $120.00 target price (up previously from $92.00) on shares of Idexx Laboratories in a research report on Wednesday, August 3rd. Canaccord Genuity reaffirmed a “buy” rating and set a $85.00 target price (up previously from $80.00) on shares of Idexx Laboratories in a research report on Tuesday, April 19th. Northcoast Research raised shares of Idexx Laboratories from a “sell” rating to a “neutral” rating in a research report on Wednesday, August 3rd. Finally, TheStreet raised shares of Idexx Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, April 29th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $99.80.

The firm has a market cap of $10.02 billion and a PE ratio of 50.73. The stock’s 50 day moving average is $97.11 and its 200 day moving average is $84.40.

Idexx Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.12. The business had revenue of $467 million for the quarter, compared to the consensus estimate of $444.83 million. During the same period in the prior year, the business earned $0.60 earnings per share. Idexx Laboratories’s revenue was up 12.9% compared to the same quarter last year. On average, equities research analysts forecast that Idexx Laboratories Inc. will post $2.36 earnings per share for the current fiscal year.

In other news, Director William T. End sold 5,000 shares of the stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $108.50, for a total value of $542,500.00. Following the completion of the sale, the director now owns 53,564 shares of the company’s stock, valued at approximately $5,811,694. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Jonathan W. Ayers sold 60,000 shares of the stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $107.69, for a total value of $6,461,400.00. The disclosure for this sale can be found here.

Several large investors recently added to or reduced their stakes in IDXX. US Bancorp DE increased its stake in Idexx Laboratories by 7.2% in the fourth quarter. US Bancorp DE now owns 39,115 shares of the company’s stock valued at $2,853,000 after buying an additional 2,612 shares during the last quarter. Advisors Asset Management Inc. increased its stake in Idexx Laboratories by 2.9% in the fourth quarter. Advisors Asset Management Inc. now owns 17,027 shares of the company’s stock valued at $1,242,000 after buying an additional 487 shares during the last quarter. Principal Financial Group Inc. increased its stake in Idexx Laboratories by 1.8% in the fourth quarter. Principal Financial Group Inc. now owns 296,034 shares of the company’s stock valued at $21,587,000 after buying an additional 5,318 shares during the last quarter. Finally, Morgan Stanley increased its stake in Idexx Laboratories by 41.3% in the fourth quarter. Morgan Stanley now owns 272,672 shares of the company’s stock valued at $19,883,000 after buying an additional 79,704 shares during the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.